Program Snapshot

The Regenerative Medicine Program (RMP) started in 2010 and is developing resources to catalyze therapeutic use of a special type of stem cells called induced pluripotent stem cells (iPSCs). RMP consists of two initiatives: (1) the Stem Cell Translation Laboratory (SCTL), headed by Dr. Ilyas Singec, within the National Center for Advancing Translational Sciences (NCATS); and (2) a Therapeutic Challenge Award to Dr. Kapil Bharti at the National Eye Institute (NEI). RMP also supports distribution of induced pluripotent stem cell lines developed by the program for laboratory and clinical research. Despite the potential benefits of iPSC technology, there are some limitations. These include the complicated process required to generate patient-specific, iPSCs safe for human use. The Regenerative Medicine Program is working to accelerate breakthroughs in the development of stem cell-based therapies for complex diseases. 

This page last reviewed on September 19, 2019